UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Predicting Circulating Human Metabolites: How Good Are We?

Chemical research in toxicology, 2009-02, Vol.22 (2), p.243-256

2009

Volltextzugriff (PDF)

Development and validation of a liquid chromatography—tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007-06, Vol.852 (1), p.582-589

2007

Volltextzugriff (PDF)

Population Pharmacokinetics of Orally Administered Duloxetine in Patients: Implications for Dosing Recommendation

Clinical pharmacokinetics, 2009-01, Vol.48 (3), p.189-197

2009

Volltextzugriff (PDF)

Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine: Analysis of a Single-Dose Phase I Study and Pooled Steady-State Data from Phase II/III Trials

Clinical pharmacokinetics, 2010-05, Vol.49 (5), p.311-321

2010

Volltextzugriff (PDF)

Duloxetine: Clinical Pharmacokinetics and Drug Interactions

Clinical pharmacokinetics, 2011-05, Vol.50 (5), p.281-294

2011

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of duloxetine following oral administration to healthy chinese subjects

Clinical pharmacokinetics, 2007-01, Vol.46 (9), p.767-775

2007

Volltextzugriff (PDF)

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

Drug metabolism and disposition, 2003-09, Vol.31 (9), p.1142

2003

Volltextzugriff (PDF)

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Current pharmaceutical design, 2005-05, Vol.11 (12), p.1475

2005

Volltextzugriff (PDF)

Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits

Clinical endocrinology (Oxford), 2000-02, Vol.52 (2), p.225-233

2000

Volltextzugriff (PDF)

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Diabetes care, 2014-09, Vol.37 (9), p.2609-2615

2014

Volltextzugriff (PDF)

Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action

Toxicologic pathology, 2017-04, Vol.45 (3), p.402-415

2017

Volltextzugriff (PDF)

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals

Pharmaceutical research, 2016-12, Vol.33 (12), p.2920-2929

2016

Volltextzugriff (PDF)

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1

Drug metabolism and disposition, 2017-02, Vol.45 (2), p.137-144

2017

Volltextzugriff (PDF)

Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose

Drug metabolism and disposition, 2015-10, Vol.43 (10), p.1477-1483

2015

Volltextzugriff (PDF)

In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine

Clinical pharmacokinetics, 2008-01, Vol.47 (3), p.191-202

2008

Volltextzugriff (PDF)

Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion

Diabetes technology & therapeutics, 2017-05, Vol.19 (5), p.305

2017

Volltextzugriff (PDF)

Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023)

Journal of pharmaceutical sciences, 2015-01, Vol.104 (1), p.207-214

2015

Volltextzugriff (PDF)

Duloxetine

Clinical pharmacokinetics, 2011-05, Vol.50 (5), p.281

2011

Volltextzugriff (PDF)

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Clinical pharmacology and therapeutics, 2003-03, Vol.73 (3), p.170-177

2003

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Drug Interactions

Clinical pharmacokinetics, 2011, Vol.50 (5), p.281-294

2011

Volltextzugriff (PDF)

Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects

Journal of clinical pharmacology, 2009-12, Vol.49 (12), p.1456-1466

2009

Volltextzugriff (PDF)

Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia

International journal of clinical pharmacology and therapeutics, 2015-06, Vol.53 (6), p.462

2015

Volltextzugriff (PDF)

Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects

Journal of clinical psychopharmacology, 2014-02, Vol.34 (1), p.9-16

2014

Volltextzugriff (PDF)

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin

Current medical research and opinion, 2012-02, Vol.28 (2), p.187-194

2012

Volltextzugriff (PDF)

Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women

Clinical pharmacokinetics, 2008-01, Vol.47 (2), p.103-109

2008

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(33)
Dissertationen
(1)

Sprache

Englisch
(34)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(28)
Humans
(25)
Male
(21)
Pharmacology & Pharmacy
(21)
Female
(19)
Adult
(18)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Middle Aged
(14)
Pharmacology. Drug Treatments
(14)
Duloxetine Hydrochloride
(13)
Animals
(10)
Thiophenes - Pharmacokinetics
(10)
Administration, Oral
(8)
Serotonin Uptake Inhibitors - Pharmacokinetics
(8)
Thiophenes - Adverse Effects
(8)
Thiophenes - Blood
(8)
Dose-Response Relationship, Drug
(7)
Drug Interactions
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predicting Circulating Human Metabolites: How Good Are We?

Development and validation of a liquid chromatography—tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma

Population Pharmacokinetics of Orally Administered Duloxetine in Patients: Implications for Dosing Recommendation

Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine: Analysis of a Single-Dose Phase I Study and Pooled Steady-State Data from Phase II/III Trials

Duloxetine: Clinical Pharmacokinetics and Drug Interactions

Pharmacokinetics and tolerability of duloxetine following oral administration to healthy chinese subjects

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1

Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose

In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine

Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion

Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023)

Duloxetine

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Clinical Pharmacokinetics and Drug Interactions

Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects

Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia

Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin

Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women

Suchergebnisse filtern